Precision Pharmaceuticals, Inc.

United States of America

Back to Profile

1-11 of 11 for Precision Pharmaceuticals, Inc. Sort by
Query
Aggregations
Date
2021 2
2020 3
Before 2020 6
IPC Class
C07F 5/02 - Boron compounds 9
A61K 31/69 - Boron compounds 7
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 7
A61K 39/00 - Medicinal preparations containing antigens or antibodies 6
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum 6
See more
Found results for  patents

1.

Compositions and methods for inhibiting arginase activity

      
Application Number 17153804
Grant Number 12054501
Status In Force
Filing Date 2021-01-20
First Publication Date 2021-08-26
Grant Date 2024-08-06
Owner Precision Pharmaceuticals, Inc. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Chen, Lijing
  • Billedeau, Roland J.
  • Stanton, Timothy F.
  • Van Zandt, Michael
  • Whitehouse, Darren
  • Jagdmann, Jr., Gunnar E.
  • Petersen, Lene Raunkjaer

Abstract

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61K 31/4245 - Oxadiazoles
  • A61K 31/69 - Boron compounds
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

2.

Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

      
Application Number 17164825
Grant Number 11370754
Status In Force
Filing Date 2021-02-01
First Publication Date 2021-05-27
Grant Date 2022-06-28
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Van Zandt, Michael
  • Savoy, Jennifer L.

Abstract

A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.

IPC Classes  ?

  • C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
  • C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 233/57 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07B 57/00 - Separation of optically-active organic compounds
  • C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07F 5/02 - Boron compounds
  • C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
  • C07C 327/22 - Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms

3.

Compositions and methods for inhibiting arginase activity

      
Application Number 16792186
Grant Number 11021495
Status In Force
Filing Date 2020-02-14
First Publication Date 2020-10-29
Grant Date 2021-06-01
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Chen, Lijing
  • Billedeau, Roland J.
  • Stanton, Timothy F.
  • Van Zandt, Michael
  • Whitehouse, Darren
  • Jagdmann, Jr., Gunnar E.
  • Petersen, Lene Raunkjær

Abstract

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61K 31/69 - Boron compounds
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/4245 - Oxadiazoles
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

4.

Compositions and methods for inhibiting arginase activity

      
Application Number 16827503
Grant Number 10844080
Status In Force
Filing Date 2020-03-23
First Publication Date 2020-07-16
Grant Date 2020-11-24
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Van Zandt, Michael
  • Whitehouse, Darren

Abstract

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/69 - Boron compounds
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

5.

Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

      
Application Number 16687394
Grant Number 10906872
Status In Force
Filing Date 2019-11-18
First Publication Date 2020-03-19
Grant Date 2021-02-02
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Van Zandt, Michael C.
  • Savoy, Jennifer L.

Abstract

A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.

IPC Classes  ?

  • C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
  • C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 233/57 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07B 57/00 - Separation of optically-active organic compounds
  • C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07F 5/02 - Boron compounds
  • C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
  • C07C 327/22 - Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms

6.

Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide

      
Application Number 15977948
Grant Number 10494339
Status In Force
Filing Date 2018-05-11
First Publication Date 2018-12-20
Grant Date 2019-12-03
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Van Zandt, Michael C.
  • Savoy, Jennifer L.

Abstract

A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.

IPC Classes  ?

  • C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07B 57/00 - Separation of optically-active organic compounds
  • C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 233/57 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
  • C07F 5/02 - Boron compounds
  • C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
  • C07C 327/22 - Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms

7.

Compositions and methods for inhibiting arginase activity

      
Application Number 16101275
Grant Number 10851118
Status In Force
Filing Date 2018-08-10
First Publication Date 2018-12-06
Grant Date 2020-12-01
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Van Zandt, Michael
  • Whitehouse, Darren

Abstract

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 31/69 - Boron compounds
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

8.

Compositions and methods for inhibiting arginase activity

      
Application Number 15853310
Grant Number 10287303
Status In Force
Filing Date 2017-12-22
First Publication Date 2018-08-09
Grant Date 2019-05-14
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Chen, Lijing
  • Billedeau, Roland J.
  • Stanton, Timothy F.
  • Van Zandt, Michael
  • Whitehouse, Darren
  • Jagdmann, Jr., Gunnar E.
  • Petersen, Lene Raunkjær

Abstract

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61K 31/69 - Boron compounds
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 31/4245 - Oxadiazoles
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

9.

Arginase inhibitor combination therapies

      
Application Number 15807357
Grant Number 11291674
Status In Force
Filing Date 2017-11-08
First Publication Date 2018-06-14
Grant Date 2022-04-05
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Makkouk, Amani
  • Gross, Matthew I.
  • Parlati, Francesco

Abstract

The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.

IPC Classes  ?

  • A61K 31/69 - Boron compounds
  • A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
  • A61K 38/20 - Interleukins
  • A61K 31/4245 - Oxadiazoles
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

10.

Compositions and methods for inhibiting arginase activity

      
Application Number 15337041
Grant Number 10065974
Status In Force
Filing Date 2016-10-28
First Publication Date 2017-05-04
Grant Date 2018-09-04
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Sjogren, Eric B.
  • Li, Jim
  • Van Zandt, Michael
  • Whitehouse, Darren

Abstract

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 31/69 - Boron compounds
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

11.

Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in PTEN/TP53

      
Application Number 15309144
Grant Number 10098880
Status In Force
Filing Date 2015-05-05
First Publication Date 2017-03-02
Grant Date 2018-10-16
Owner PRECISION PHARMACEUTICALS, INC. (USA)
Inventor
  • Vali, Shireen
  • Usmani, Shahabuddin
  • Sultana, Zeba
  • Kumar, Ansu
  • Abbasi, Taher
  • Vidva, Robinson

Abstract

The present disclosure relates to a method of treating cancer using a composition comprising Nelfinavir, Metformin, Rosuvastatin, optionally along with a pharmaceutically acceptable excipient. The said composition is used for the treatment of cancer caused due to aberration in PTEN gene, optionally along with aberration in TP53 gene and related genes selected from group comprising PI3K, CDKN2A, MDM2 and MDM4.

IPC Classes  ?

  • A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine